EUVIMEDEUVIMED entdecken
Studienprotokoll

Comparison of low - dose and standard - dose rituximab (rheumatoid arthritis protocol) in the treatment of pemphigus vulgaris: A retrospective observational study

Karishni Chittarvu, Sudharani Chintagunta, Navya Suvidha Cindhe, Hitha Alu James, B. Raghu Kiran

Journal of Skin and Sexually Transmitted Diseases · 2025

DOI: 10.25259/jsstd_118_2025 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Journal of Skin and Sexually Transmitted Diseases, 2025. Verfasst von Karishni Chittarvu und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Pemphigus vulgaris (PV) is a chronic autoimmune blistering disorder. Rituximab is now considered first-line therapy for moderate-to-severe PV, but the optimal dosing regimen remains debated, especially in resource-limited settings. The objective of the study is to compare the clinical efficacy, safety, and cost-effectiveness of low-dose rituximab with the standard rheumatoid arthritis (RA) protocol in patients with moderate-to-severe PV. Materials and Methods: This retrospective observational study was conducted at a tertiary dermatology center between January 2022 and December 2024. Fifty biopsy and direct immunofluorescence-confirmed PV patients were divided into two groups: Group A (low-dose rituximab: 500 mg IV on days 0 and 15) and Group B (standard RA protocol: 1000 mg IV on days 0 and 15). Demographics, baseline pemphigus disease area index (PDAI) scores, prior treatments, time to disease control, remission rates, relapse at 6, 9, and 12 months, and adverse events were recorded. Statistical analysis was performed using Statistical Package for the Social Sciences version 25.0; P < 0.05 was considered statistically significant.

Results

The mean baseline PDAI scores were comparable between groups ( P > 0.05). Complete remission (CR) was achieved in 80% (Group A) and 84% (Group B) ( P = 1.000). CR off therapy at 6 months was 68% versus 72% ( P = 1.000). Relapse rates at 6, 9, and 12 months were similar ( P > 0.05). Mean time to disease control was slightly longer in Group A (5.6 ± 1.2 weeks) than in Group B (4.9 ± 1.1 weeks) ( P < 0.001). Adverse events were mild infusion-related reactions in both groups. Low-dose therapy was significantly more cost-effective.

Limitations

Retrospective design, relatively small sample size, and absence of immunological marker assessment.

Conclusion

Low-dose rituximab is as effective and safe as the RA protocol for moderate PV, with comparable relapse rates and a substantial cost advantage. It may be considered a pragmatic first-line option, especially in resource-constrained settings.

Zitieren

APA

Chittarvu, K., Chintagunta, S., Cindhe, N. S., James, H. A., & Kiran, B. R. (2025). Comparison of low - dose and standard - dose rituximab (rheumatoid arthritis protocol) in the treatment of pemphigus vulgaris: A retrospective observational study. Journal of Skin and Sexually Transmitted Diseases. https://doi.org/10.25259/jsstd_118_2025

Vancouver

Chittarvu K, Chintagunta S, Cindhe NS, James HA, Kiran BR. Comparison of low - dose and standard - dose rituximab (rheumatoid arthritis protocol) in the treatment of pemphigus vulgaris: A retrospective observational study. Journal of Skin and Sexually Transmitted Diseases. 2025. doi:10.25259/jsstd_118_2025

BibTeX
@article{Chittarvu2025,
  author = {Chittarvu, Karishni and Chintagunta, Sudharani and Cindhe, Navya Suvidha and James, Hitha Alu and Kiran, B. Raghu},
  title = {Comparison of low - dose and standard - dose rituximab (rheumatoid arthritis protocol) in the treatment of pemphigus vulgaris: A retrospective observational study},
  journal = {Journal of Skin and Sexually Transmitted Diseases},
  year = {2025},
  doi = {10.25259/jsstd_118_2025}
}
Kostenlos starten →